Genomic Alterations and Outcomes With Fixed-Duration Ibrutinib plus Venetoclax: Results From the Phase 3 GLOW Study in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
Key words
CLL, genomic aberration, gene mutation, ibrutinib, chemoimmunotherapy, chronic lymphocytic leukemia
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined